Galectin-3: therapeutic targeting in liver disease
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The rising incidence of liver diseases is a worldwide healthcare concern. However, the therapeutic options to manage chronic inflammation and fibrosis, the processes at the basis of morbidity and mortality of liver diseases, are very limited. Galectin 3 (Gal-3) is a protein implicated in fibrosis in multiple organs. Several Gal-3 inhibitors are currently in clinical development. AREAS COVERED: This review describes our current understanding of the role of Gal-3 in chronic liver diseases, with special emphasis on fibrosis. Also, we review therapeutic advances based on Gal-3 inhibition, describing drug properties and their current status in clinical research. EXPERT OPINION: Currently, the known effects of Gal-3 point to a direct activation of the NLRP3 inflammasome leading to its activation in liver macrophages and activated macrophages play a key role in tissue fibrogenesis. However, more research is needed to elucidate the role of Gal-3 in the different activation pathways, dissecting the intracellular and extracellular mechanisms of Gal-3, and its role in pathogenesis. Gal-3 could be a target for early therapy of numerous hepatic diseases and, given the lack of therapeutic options for liver fibrosis, there is a strong pharmacologic potential for Gal-3-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammasomes: mechanism of assembly, regulation and signalling
Broz, P., & Dixit, V. M. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.58 · Cited by 3,500
Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis
Henderson, N. C., Mackinnon, A. C., Farnworth, S. L., Kipari, T., Haslett, C., Iredale, J. P., Liu, F.-T., Hughes, J., & Sethi, T. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070726 · Cited by 562 · cited 1×
“Generally, Gal-3 expression is associated with pro-fibrotic activity due to its ability to regulate the activity of fibroblasts and macrophages in chronically inflamed organs [30].”
BackgroundSelf-citationBrewer, C. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00364-0 · Cited by 435
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430 · cited 1×
“With the excessive deposition of extracellular matrix molecules and collagen by activated HSC, the formation of fibrotic ridges and bridging fibrosis results in changes in the tissue architecture and further damage, eventually leading to organ failure [93,94].”
BackgroundSelf-citationCritical role of galectin-3 in phagocytosis by macrophages
Sano, H., Hsu, D. K., Apgar, J. R., Yu, L., Sharma, B. B., Kuwabara, I., Izui, S., & Liu, F.-T. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317592 · Cited by 429
Burguillos, M. A., Svensson, M., Schulte, T., Boza-Serrano, A., Garcia-Quintanilla, A., Kavanagh, E., Santiago, M., Viceconte, N., Oliva-Martin, M. J., Osman, A. M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.012 · Cited by 365 · cited 2×
“Also, Gal-3 is a paracrine ligand for the Toll-like receptor 4 (TLR4) [24], binds and regulates the activity of the T cell receptor 4-1BB [25], induces platelet aggregation via binding to Dectin-1 [26], and binds to the endogenous triggering receptor expressed on myeloid cells 2 (TREM2), driving…”
BackgroundChalasani, N., Abdelmalek, M. F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., Noureddin, M., Pyko, M., Shiffman, M., Sanyal, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.296 · Cited by 358 · cited 2×
“These studies revealed no significant impact of belapectin on fibrosis or activity score, and liver-related outcomes did not differ significantly between the studied cohorts [119].”
BackgroundResultBoza-Serrano, A., Ruiz, R., Sanchez-Varo, R., García-Revilla, J., Yang, Y., Jimenez-Ferrer, I., Paulus, A., Wennström, M., Vilalta, A., Allendorf, D., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02013-z · Cited by 357 · cited 1×
“…receptor 4 (TLR4) [24], binds and regulates the activity of the T cell receptor 4-1BB [25], induces platelet aggregation via binding to Dectin-1 [26], and binds to the endogenous triggering receptor expressed on myeloid cells 2 (TREM2), driving microglial activation in Alzheimer’s disease [27,28].”
BackgroundInzaugarat, M. E., Johnson, C. D., Holtmann, T. M., McGeough, M. D., Trautwein, C., Papouchado, B. G., Schwabe, R., Hoffman, H. M., Wree, A., & Feldstein, A. E. (2019) · Hepatology · doi:10.1002/hep.30252 · Cited by 148 · cited 1×
“Studies of transgenic animal models have shown that the NLRP3 inflammasome also plays an important role in the development of liver fibrosis, by activation of hepatic stellate cells [100].”
BackgroundIt’s all about the spaces between cells: role of extracellular matrix in liver fibrosis
Khurana, A., Sayed, N., Allawadhi, P., & Weiskirchen, R. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-2948 · Cited by 79
Cited by
Gut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease
Raya Tonetti, F., Eguileor, A., Mrdjen, M., Pathak, V., Travers, J., Nagy, L. E., & Llorente, C. (2024) · Hepatology · doi:10.1097/hep.0000000000000924 · Cited by 78
Sakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502978122 · Cited by 46
(2025) · doi:10.1101/2025.02.25.640203 · Cited by 45
Macrophage heterogeneity in liver fibrosis
Wang, W., Li, S., Liu, Y., Ding, X., Yang, Y., Chen, S., Cao, J., Tacke, F., Dong, W., & Lan, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639455 · Cited by 8
Metadata
- Authors
- Mackinnon, A. C., Tonev, D., Jacoby, B., Pinzani, M., & Slack, R. J.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2023-09-02
- Volume
- 27
- Issue
- 9
- Pages
- 779-791
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W4386725502
- Cited by
- 38
- References
- 10
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Galectin-3: therapeutic targeting in liver disease. https://app.cochat.ai/papers/10.1080/14728222.2023.2258280
- The paper
- Mackinnon, A. C., Tonev, D., Jacoby, B., Pinzani, M., & Slack, R. J. (2023). Galectin-3: therapeutic targeting in liver disease. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2023.2258280
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.